M.d. Anderson Cancer Center

This study tested two drugs, omacetaxine and venetoclax, in 24 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that returned or didn't respond to treatment and had a RUNX1 gene change. The goal was to find the best dose and see if the combination could …

This study tested whether using MRI to guide radiation therapy can better control central lung tumors and reduce side effects compared to standard CT-guided radiation. Only 3 people took part before the study was stopped early. The goal was to see if the approach is safe and feas…

This early-stage study tested the drug belantamab mafodotin (Blenrep) as a maintenance therapy to prevent multiple myeloma from returning after a stem cell transplant. It included 6 patients with relapsed or refractory disease. The study was terminated early, so results are limit…

This study tested a combination of two drugs (nab-paclitaxel and alpelisib) given before surgery to people with a specific type of aggressive breast cancer (triple-negative) that had stopped responding to standard chemotherapy. The goal was to see if the combo could shrink tumors…

This early-phase study tested a new drug combination (ipilimumab plus MGN1703) in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the highest safe dose of MGN1703 when given with ipilimumab. Up to 60 participants wer…

This study tested whether a combination of two drugs, daratumumab and pomalidomide, could help control multiple myeloma that has returned after a stem cell transplant. The study included 13 adults with relapsed disease. The goal was to see if this maintenance therapy could lead t…

This study looked at adding the targeted drug inotuzumab ozogamicin to standard chemotherapy before and after a stem cell transplant for people with certain types of leukemia or lymphoma. The goal was to see if it was safe and could help control the cancer. The study was stopped …

This early-phase trial tested a treatment combining donor natural killer (NK) cells from cord blood with chemotherapy in children and young adults whose solid tumors had returned or stopped responding to standard therapy. The main goals were to check safety and find the best dose…